{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:42Z","timestamp":1790666982633,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.canlet.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T08:32:19Z","timestamp":1581496339000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["IRE1\u03b1-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells"],"prefix":"10.1016","volume":"476","author":[{"given":"Qiang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-xiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-zhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-di","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.02.007_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568009033333754","article-title":"Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation","volume":"3","author":"Yusuf","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2020.02.007_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2020.02.007_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60761-416-6_21","article-title":"Circumventing tumor resistance to chemotherapy by nanotechnology","volume":"596","author":"Liang","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2020.02.007_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2020.02.007_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2016.03.025","article-title":"Cancer chemoresistance; biochemical and molecular aspects: a brief overview","volume":"89","author":"Kachalaki","year":"2016","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.canlet.2020.02.007_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/09674845.2013.11669927","article-title":"DNA damage repair and tolerance: a role in chemotherapeutic drug resistance","volume":"70","author":"Salehan","year":"2013","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2020.02.007_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2020.02.007_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade","volume":"370","author":"Chen","year":"2016","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.02.007_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2020.02.007_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm2199","article-title":"Signal integration in the endoplasmic reticulum unfolded protein response","volume":"8","author":"Ron","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.02.007_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nri2359","article-title":"The endoplasmic reticulum stress response in immunity and autoimmunity","volume":"8","author":"Todd","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2020.02.007_bib12","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0092-8674(93)90648-A","article-title":"Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase","volume":"73","author":"Cox","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.02.007_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0092-8674(93)90521-Q","article-title":"A transmembrane protein with a cdc2+CDC28-related kinase activity is required for signaling from the ER to the nucleus","volume":"74","author":"Morl","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.02.007_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrc3800","article-title":"The impact of the endoplasmic reticulum protein-folding environment on cancer development","volume":"14","author":"Wang","year":"2014","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.02.007_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-012513-104649","article-title":"The role of endoplasmic reticulum stress in human pathology","volume":"10","author":"Oakes","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.canlet.2020.02.007_bib16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nrc1505","article-title":"The role of the unfolded protein response in tumour development: friend or foe?","volume":"4","author":"Ma","year":"2004","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.02.007_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-14-1490","article-title":"Endoplasmic reticulum stress\u2013activated cell reprogramming in oncogenesis","volume":"5","author":"Chevet","year":"2015","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2020.02.007_bib18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nrd2755","article-title":"Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities","volume":"7","author":"Kim","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2020.02.007_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00018-015-2052-6","article-title":"The endoplasmic reticulum: structure, function and response to cellular signaling","volume":"73","author":"Schwarz","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"10.1016\/j.canlet.2020.02.007_bib20","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1038\/oncsis.2017.72","article-title":"Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers","volume":"6","author":"Avril","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2020.02.007_bib21","first-page":"277","article-title":"The unfolded protein response as a target for cancer therapy","volume":"1846","author":"Nagelkerke","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2020.02.007_bib22","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-07-0625","article-title":"The unfolded protein response regulator GRP78\/BiP as a novel target for increasing chemosensitivity in malignant gliomas","volume":"67","author":"Pyrko","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.02.007_bib23","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1158\/0008-5472.CAN-05-0754","article-title":"Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment","volume":"65","author":"Dong","year":"2005","journal-title":"Canc. Res."},{"issue":"e21\u201311","key":"10.1016\/j.canlet.2020.02.007_bib24","first-page":"29","article-title":"Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy","volume":"32","author":"Lin","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.canlet.2020.02.007_bib25","doi-asserted-by":"crossref","first-page":"20915","DOI":"10.1074\/jbc.M212328200","article-title":"Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation","volume":"278","author":"Reddy","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.02.007_bib26","first-page":"8592","article-title":"Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines","volume":"63","author":"Tanabe","year":"2003","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.02.007_bib27","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1038\/sj.onc.1210289","article-title":"Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines","volume":"26","author":"Igarashi","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.02.007_bib28","doi-asserted-by":"crossref","first-page":"40692","DOI":"10.18632\/oncotarget.5827","article-title":"A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1\/XBP1","volume":"6","author":"Ming","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.02.007_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrc1569","article-title":"Colorectal cancer screening: prospects for molecular stool analysis","volume":"5","author":"Davies","year":"2005","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.02.007_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2016.04.018","article-title":"Overcoming treatment resistance in cancer: current understanding and tactics","volume":"387","author":"Wu","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.02.007_bib31","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","article-title":"Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition","volume":"69","author":"Dallas","year":"2009","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.02.007_bib32","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.3748\/wjg.v22.i30.6876","article-title":"Mechanisms of drug resistance in colon cancer and its therapeutic strategies","volume":"22","author":"Hu","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2020.02.007_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1053\/j.gastro.2009.09.049","article-title":"Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKK\u03b2 independent of hydroxylase activity","volume":"138","author":"Xue","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2020.02.007_bib34","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1038\/onc.2017.284","article-title":"Knockdown of IRE1\u03b1 inhibits colonic tumorigenesis through decreasing \u03b2-catenin and IRE1\u03b1 targeting suppresses colon cancer cells","volume":"36","author":"Li","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.02.007_bib35","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/ncomms4528","article-title":"Hepatic IRE1\u03b1 regulates fasting-induced metabolic adaptive programs through the XBP1s-PPAR\u03b1 axis signaling","volume":"5","author":"Shao","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2020.02.007_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2019.04.011","article-title":"Lemur tyrosine kinase 2 acts as a positive regulator of NF-\u03baB activation and colon cancer cell proliferation","volume":"454","author":"Zhang","year":"2019","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.02.007_bib37","doi-asserted-by":"crossref","first-page":"E869","DOI":"10.1073\/pnas.1115623109","article-title":"The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule","volume":"109","author":"Cross","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.02.007_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/jb\/mvn091","article-title":"Human HRD1 promoter carries a functional unfolded protein response element to which XBP1 but not ATF6 directly binds","volume":"144","author":"Yamamoto","year":"2008","journal-title":"J. Biochem."},{"key":"10.1016\/j.canlet.2020.02.007_bib39","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","article-title":"Molecular mechanisms of drug resistance and its reversal in cancer","volume":"36","author":"Kartal-Yandim","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.canlet.2020.02.007_bib40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.02.007_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/boc.201800050","article-title":"The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance","volume":"111","author":"Madden","year":"2019","journal-title":"Biol. Cell."},{"key":"10.1016\/j.canlet.2020.02.007_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/hep.29871","article-title":"Dual role for inositol-requiring enzyme 1\u03b1 in promoting the development of hepatocellular carcinoma during diet-induced obesity in mice","volume":"68","author":"Wu","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2020.02.007_bib43","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41467-018-05763-8","article-title":"Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy","volume":"9","author":"Logue","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2020.02.007_bib44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI95873","article-title":"Pharmacological targeting of MYC-regulated IRE1\/XBP1 pathway suppresses MYC-driven breast cancer","volume":"128","author":"Zhao","year":"2018","journal-title":"J. Clin. Invest."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520300690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520300690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:46:56Z","timestamp":1759592816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520300690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":44,"alternative-id":["S0304383520300690"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.02.007","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IRE1\u03b1-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}